Select Page

About GTP Bioways

GTP Bioways is an expert and fast-growing contract development and manufacturing organization (CDMO) specialised in process development and manufacturing of antibodies, proteins, bioconjugates and nanodrugs.

Our history

GTP Bioways is born out of the integration of several companies under one roof. It is their complementary expertise and long-standing experience in providing customised services to the biopharma industry that make our strength.

Today, with a team of almost 100 dedicated collaborators, GTP Bioways is focused on providing end-to-end services to support our customers at all stages of their drug development, from R&D to commercial manufacturing.

2000 - Inception of GTP Technology

Custom protein production and process development services

2019 - Creation of VBI Therapeutics

by Alain SAINSOT (former industrial director at Pierre Fabre and founder of Amatsi Group)

2019 - Creation of V-nano, a VBI Therapeutics company

CDMO expert in nanoformulation development and fill & finish

2019 - Acquisition of GTP Technology by VBI Therapeutics

2020 - GTP Biologics operated by VBI Therapeutics

Former Pierre Fabre CDMO facility at St-Julien-en-Genevois becomes GTP Biologics, operated by VBI Therapeutics through a strategic partnership with Fareva

2021 - VBI Therapeutics becomes GTP Bioways

Full CDMO services for recombinant mAbs and proteins from early development up to clinics

Expert & flexible CDMO for biologics, antibody conjugates and nanodrugs

GTP Bioways is a customer-centric and science-driven CDMO committed to offering uniquely customised process development and GMP manufacturing services for biologics, antibody-drug conjugates and nanodrugs.

With our cutting-edge facilities located in France, GTP Bioways can support biopharma companies from preclinical to commercial production of their innovative therapies.

Drawing on its expertise in solving difficult client problems, our team strives to offer a tailored approach, finely tuned to overcome your specific challenges. We are unique in our ability to develop agile solutions for challenging projects such as the production of difficult-to-express proteins, the development of atypical purification schemes or the formulation of nano-enabled products (NEP).

Advanced Biodesign

A science-driven and customer-centric CDMO

We are very proud of our teams of seasoned and highly qualified professionals and their extensive technical experience across all stages of the biopharmaceutical value chain, from R&D to cGMP production including aseptic filling.

Infusing a client-first corporate culture is a major priority of GTP Bioways’ management. We believe that empathy, integrity and transparency are key to ensuring long-lasting relationships with our customers and to the success of their programmes. We are proud to say that our customers praise our synergic approach.

Management team

The GTP Bioways management team and all GTP Bioways collaborators have a strong background in the development and manufacturing of innovative therapies.
Alain SAINSOT

Alain SAINSOT

GTP Bioways

President

Eric DEVIC

Eric DEVIC

GTP Tech

CEO

Sandrine LAUTHIER

Sandrine LAUTHIER

GTP Biologics

Director

Franck PAVAN

Franck PAVAN

GTP Nano

Director

Vincent RIVERA

Vincent RIVERA

GTP Immuno

CEO

Séverine HOUNTONDJI

Séverine HOUNTONDJI

GTP Bioways

Director of business development and marketing

Our expertise spans all stages of therapeutics development from R&D to commercial production

Over 20 Years’ experience

Highly skilled collaborators

Different protein projects

GMP success rate over the past 10 years

Discover more about GTP Bioways services

GTP Bioways

Our facilities

GTP Bioways

Our approach

GTP Bioways

Our references